Global COVID-19 Pipeline Report 2021 - Comprehensive Insights About 400+ Companies and 400+ Pipeline Drugs

News provided by

Oct 11, 2021, 08:45 ET

DUBLIN, Oct. 11, 2021 /PRNewswire/ -- The "COVID-19 - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This "COVID-19 - Pipeline Insight, 2021" report provides comprehensive insights about 400+ companies and 400+ pipeline drugs in COVID-19 pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence COVID-19 R&D. The therapies under development are focused on novel approaches to treat/improve COVID-19.

COVID-19 Emerging Drugs Chapters

This segment of the COVID-19 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

COVID-19 Emerging Drugs

REGN-COV2: Regeneron Pharmaceuticals

REGN-COV2 Antibody Cocktail (Casirivimab and Imdevimab; REGN10933 + REGN10987) is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company's VelocImmune mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population.

Bucillamine: Revive Therapeutics

Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC.2 The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other antioxidant and anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19.

Mupadolimab (CPI-006): Corvus Pharmaceuticals

Mupadolimab (CPI-006) is an antibody that possesses dual properties: binding to CD73, which may reduce its suppression of the immune response via the adenosine pathway; and activating B cells, which may result in increased antibody production to antigens and the generation of memory B cells to extend protection.

VERU-111: Veru Inc.

Sabizabulin is a cytoskeleton disruptor which by causing microtubule depolymerization has both anti-viral and anti-inflammatory activity and could be effective against the SARS-CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to be transported, replicated, assembled, and released from the cell. In addition, microtubule depolymerization drugs that target the "colchicine binding site" of microtubules, like sabizabulin, also have strong anti-inflammatory effects, including the potential to treat the cytokine release syndrome (cytokine storm) and septic shock induced by the SARS-CoV-2 viral infection that is associated with high COVID-19 mortality rates.

Sarconeos (BIO101): Biophytis

Sarconeos (BIO101) is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity in various age-related and muscular wasting conditions.

Leronlimab: CytoDyn

Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of COVID-19 infection.

Tocilizumab: Hoffmann-La Roche

Actemra/RoActemra (Tocilizumab) is being developed by Hoffmann-La Roche in phase III stage of development for the treatment of Severe COVID-19 Pneumonia. Actemra/RoActemra is an anti-IL-6 receptor biologic approved to treat moderate-to-severe active rheumatoid arthritis (RA) in adults. The IL-6 protein triggers the body's immune and inflammatory response to fight infections. But, in the case of those patients where their immune system overreacts, inhibiting IL-6 could keep the body from attacking itself.

In Mar 2020, Roche received Chinese approval for the use of the drug to treat patients developing severe complications from Covid-19.

The new randomized, double-blind, placebo-controlled Phase III trial will be conducted in alliance with the US Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). It will assess the safety and efficacy of Actemra in combination with standard of care compared to placebo.

COVID-19: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses COVID-19 therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 drugs.

Key Questions Answered

How many companies are developing COVID-19 drugs?
How many COVID-19 drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of COVID-19?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the COVID-19 therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for COVID-19 and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players

Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
TC BioPharm
Syntax for Science, S.L
Shaperon
Renibus Therapeutics
Quercis Pharma
Pharmenterprises
Pharmamel S.L.
Orpheris
OPKO Health
Oncotelic Inc.
Notitia Biotechnologies Company
Jazz Pharmaceuticals
Ionis Pharmaceuticals
Inotrem
Grifols Therapeutics LLC
Grifols Therapeutics LLC
Grifols Therapeutics
Grifols Therapeutics
Globavir Biosciences
Genentech, Inc.
FSD Pharma
Faron Pharmaceuticals
Evergreen Therapeutics
Enlivex Therapeutics
Eiger BioPharmaceuticals
Direct Biologics
Debiopharm
Clene Nanomedicine
Chiesi Farmaceutici S.p.A.
Cadila Healthcare Limited
Biotest
BeiGene
Apeiron Biologics
AgelessRx
AbbVie/Apotex
Telios Pharmaceuticals
Rapa Therapeutics
Organicell Regenerative Medicine
Miltenyi Biomedicine
MedRegen LLC
Kiadis Pharma
Kamada
Cellularity Incorporated
Bio-Thera Solutions
3M
Sironax
Pfizer
Oncovir
Ology Bioservices
Neutrolis
NeoImmune Tech
Natureceuticals Sdn Bhd
Medicine Invention
Kiadis Pharma
Grand Medical
Frontier Biotechnologies
Emergent Biosolutions
Codagenix
Cellenkos
AlloVir
Bausch Health Americas
AiCuris
AgenTus Therapeutics
4D Pharma

Key Products

T3 solution for injection
TCB008
Bemiparin
NuSepin
RBT-9
IQC-950AN
Treamid
Melatonin
OP-101
Rayaldee
OT-101
NBT-NM108
Defibrotide
ISIS 721744
Nangibotide
Alpha1-PI
Convalescent anti-SARS-CoV-2 MBT Plasma
GAMUNEX-C
Prolastin
GBV 006
Tenecteplase
FSD201
IFN beta-1a
EG-HPCP-03a
Allocetra-OTS
Pegylated interferon lambda
DB-001
Alisporivir
CNM-ZnAg
Poractant alfa (Curosurf)
Pegylated Interferon-a2b
Trimodulin
BGB-DXP593
APN01
Naltrexone
Interferon beta-1a
TL-895
RAPA-501
Organicell Flow
IMP
MRG-001
KDS-1000
Kamada Anti-SARS-CoV-2
CYNK-001
BAT2020
Povidine iodine nasal swabs
SIR1-365
PF-07304814
Poly-ICLC
ADM03820
NTR-441
NT-I7
Nuvastatic
COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
K-NK-ID101
STC3141
FB2001
COVID-HIGIV
COVI-VAC
CK0802
Partially HLA-matched SARS-CoVSTs
Virazole
AIC649
agenT-797
MRx-4DP0004
Vaxcelerate

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/gcj0rs

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets